PRECISION BIOSCIENCES INC DTIL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-7.2
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $34.3M | -$45.7M | — | — | $92.2M |
| 2024 | $68.7M | $7.2M | — | — | $56.4M |
| 2023 | $48.7M | -$61.3M | — | — | $18.9M |
| 2022 | $25.1M | -$111.6M | — | — | $60.4M |
| 2021 | $115.5M | -$30.6M | — | — | $91.2M |
| 2020 | $24.3M | -$109.0M | — | — | $44.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Buehler Kevin | director | 2026-05-20 | Option exercise | 21,000 | — |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.2 (distress)
- Working capital / assets 0.711
- Retained earnings / assets -3.421
- EBIT / assets -0.338
- Equity / liabilities 1.484
Source: SEC EDGAR filings · CIK 0001357874 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.